Marker Therapeutics, Inc. (MRKR): Cash & Equivalents
$16.07M
As of 2025-12-31
$11.33M
As of 2026-06-30
+10.9%
3-year compound annual growth
-5.5%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $16.07M | -16.3% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $19.19M | +27.0% | 2026-03-18, Balance as of period end |
| 2023-12-31 | $15.11M | +28.3% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $11.78M | -72.2% | 2024-03-26, Balance as of period end |
| 2021-12-31 | $42.35M | +98.3% | 2023-03-22, Balance as of period end |
| 2020-12-31 | $21.35M | -51.4% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $43.90M | -28.9% | 2021-03-09, Balance as of period end |
| 2018-12-31 | $61.75M | n/m | 2020-03-12, Balance as of period end |
| 2017-12-31 | $5.13M | n/a | 2019-03-15, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $16.07M | -16.3% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $109.52M | +71.0% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $8.24M | -8.5% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $345.1K | -44.9% |
| TherapeuticsMD, Inc. (TXMD) | 2024-12-31 | $5.06M | +16.9% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $90.0K | -86.7% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $101.58M | -68.8% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $125.14M | -41.1% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $3.09M | -44.0% |
Compare MRKR, CAMP, CRVO, CPHI side by side · Screen every company in Pharmaceutical Preparations ↗